DK0687184T3 - Recombinant adenoviruses and their use in gene therapy for the treatment of eye diseases - Google Patents

Recombinant adenoviruses and their use in gene therapy for the treatment of eye diseases

Info

Publication number
DK0687184T3
DK0687184T3 DK94908383T DK94908383T DK0687184T3 DK 0687184 T3 DK0687184 T3 DK 0687184T3 DK 94908383 T DK94908383 T DK 94908383T DK 94908383 T DK94908383 T DK 94908383T DK 0687184 T3 DK0687184 T3 DK 0687184T3
Authority
DK
Denmark
Prior art keywords
eye diseases
treatment
recombinant adenoviruses
gene therapy
adenoviruses
Prior art date
Application number
DK94908383T
Other languages
Danish (da)
Inventor
Pascale Briand
Michel Perricaudet
Original Assignee
Inst Nat Sante Rech Med
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Aventis Pharma Sa filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK0687184T3 publication Critical patent/DK0687184T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The use of defective recombinant adenoviruses containing an inserted gene for preparing a pharmaceutical useful for treating eye diseases is disclosed.
DK94908383T 1993-03-03 1994-02-28 Recombinant adenoviruses and their use in gene therapy for the treatment of eye diseases DK0687184T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (en) 1993-03-03 1993-03-03 Recombinant viruses and their use in gene therapy.
PCT/FR1994/000220 WO1994020146A1 (en) 1993-03-03 1994-02-28 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases

Publications (1)

Publication Number Publication Date
DK0687184T3 true DK0687184T3 (en) 2002-10-28

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94908383T DK0687184T3 (en) 1993-03-03 1994-02-28 Recombinant adenoviruses and their use in gene therapy for the treatment of eye diseases

Country Status (15)

Country Link
EP (1) EP0687184B1 (en)
JP (1) JP3835809B2 (en)
AT (1) ATE220923T1 (en)
AU (1) AU693782B2 (en)
CA (1) CA2154355A1 (en)
DE (1) DE69431046T2 (en)
DK (1) DK0687184T3 (en)
ES (1) ES2181710T3 (en)
FR (1) FR2702152B1 (en)
HU (1) HU218900B (en)
NO (1) NO319571B1 (en)
NZ (1) NZ262135A (en)
PT (1) PT687184E (en)
WO (1) WO1994020146A1 (en)
ZA (1) ZA941426B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
FR2717823B1 (en) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2726575B1 (en) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY
FR2717824B1 (en) 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2718150B1 (en) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
JP2004500369A (en) * 1999-12-30 2004-01-08 アバンテイス・フアルマ・エス・アー Use of a vector containing a nucleic acid encoding an anti-angiogenic factor to treat corneal neovascularization
FR2803207B1 (en) * 1999-12-30 2004-04-30 Aventis Pharma Sa USE OF A VECTOR COMPRISING A NUCLEIC ACID ENCODING AN ANTI-ANGIOGENIC FACTOR FOR THE TREATMENT OF CORNEAL NEOVASCULARIZATIONS
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
NZ546983A (en) 2003-11-24 2009-05-31 Canji Inc Reduction of dermal scarring
JP4944032B2 (en) 2004-09-13 2012-05-30 ジェンザイム・コーポレーション Multimeric construct
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation Vegf antagonist compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928169T2 (en) * 1988-09-13 1998-02-26 Biosource Tech Inc Composition for the treatment of degenerative diseases of the nervous system
AU655279B2 (en) * 1991-04-05 1994-12-15 Edison Animal Biotechnology Center Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences

Also Published As

Publication number Publication date
HUT73215A (en) 1996-06-28
EP0687184A1 (en) 1995-12-20
NZ262135A (en) 2000-12-22
AU693782B2 (en) 1998-07-09
NO953329D0 (en) 1995-08-24
FR2702152B1 (en) 1995-05-24
ES2181710T3 (en) 2003-03-01
AU6144494A (en) 1994-09-26
EP0687184B1 (en) 2002-07-24
JPH08509208A (en) 1996-10-01
WO1994020146A1 (en) 1994-09-15
NO953329L (en) 1995-08-24
CA2154355A1 (en) 1994-09-15
NO319571B1 (en) 2005-08-29
PT687184E (en) 2002-12-31
FR2702152A1 (en) 1994-09-09
ATE220923T1 (en) 2002-08-15
HU9502573D0 (en) 1995-10-30
HU218900B (en) 2000-12-28
DE69431046D1 (en) 2002-08-29
ZA941426B (en) 1994-10-04
DE69431046T2 (en) 2003-02-13
JP3835809B2 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
DK0687184T3 (en) Recombinant adenoviruses and their use in gene therapy for the treatment of eye diseases
DE69630890D1 (en) PEPTID-IMITATING SUBSTANCES IN CANCER THERAPY
DK0698108T4 (en) Adenoviral vectors of animal origin and their use in gene therapy
DK19488D0 (en) RADIATION SYSTEM FOR USE IN MEDICAL TREATMENT OF NOSE AND NECK PASSAGES
DK0751709T3 (en) Use of Bcl-2 in the manufacture of drugs for therapeutic treatment and prevention of diseases
DK25087D0 (en) ENDOSCOPE FOR CONDUCTING RADIATED RADIATIONS AND USE IN MEDICAL TREATMENT
DK85786D0 (en) BIOLOGICALLY ACTIVE FRAGMENTS OF HUMAN ANTIHAEMOPHILIC FACTOR AND METHOD OF PRODUCING THEREOF
DK0668763T3 (en) Use of Phenserin in the manufacture of drugs for the treatment of cognitive disorders
NO972451L (en) Heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof
DK0517820T3 (en) Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excessive obesity
JPS57193411A (en) Prevention of prostatic hyperplasia and therapeutical drug
ATE247709T1 (en) 3'UTR OF THE HUMAN PROHIBITIN GENE
EP0607776A3 (en)
NO931413D0 (en) METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES
SG50419A1 (en) Methods of therapeutic and anaesthetic treatment and preparations therefor
UA29648A (en) Method for treatment of chemical burns of esophagus
MX9706569A (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy.
UA12890A (en) METHOD OF ACUPUCHTURE
ZA93199B (en) An apparatus for use in therapeutic and/or medical treatment.
UA22007A (en) Method for treating chronic non-specific prostatitis
GEP19981480B (en) Method for Treating Vertebral Column
DE69822234D1 (en) Use of olanzapine in the manufacture of a medicament for neuroprotection
UA8280A (en) Method for treating psoriasis
DK136993D0 (en) PROCEDURE AND APPARATUS FOR LOCATING AND TREATING DAMAGED OR FUNCTIONALLY DISTURBED AREAS IN A PATIENT'S BRAIN